Furthermore, a ribonucleoprotein complex (LncRNA MALAT1 and HUR) down-regulated the expression of CD133+ phenotype and inhibited the stem cell properties of BCSCs, leading to tumorigenesis and metastasis failure both in MCF-7 and MDA-MB-231 (Latorre et al., 2016), revealing the indirect mechanism of CD133 and drug resistance in BC. The gene discussed is PROM1; the disease is breast cancer.